Somatostatin receptor imaging in cns tumours using111IN-octreotide

C. L. Maini, R. Sciuto, A. Tofani, A. Ferraironi, C. M. Carapella, E. Occhipinti, M. Mottolese, M. Crecco

Research output: Contribution to journalArticle

Abstract

This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of111In-octreotide. An uptake index was computed using tumourz non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immuno- histochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: Very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post- surgical follow-up and in the assessment of differentiation in glial tumours.

Original languageEnglish
Pages (from-to)756-766
Number of pages11
JournalNuclear Medicine Communications
Volume16
Issue number9
Publication statusPublished - 1995

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Maini, C. L., Sciuto, R., Tofani, A., Ferraironi, A., Carapella, C. M., Occhipinti, E., Mottolese, M., & Crecco, M. (1995). Somatostatin receptor imaging in cns tumours using111IN-octreotide. Nuclear Medicine Communications, 16(9), 756-766.